Phenylpiracetam hydrazide

Overview

Phenylpiracetam hydrazide is a non-peptide racetam-class small molecule — specifically a pyrrolidinone acetohydrazide in which the terminal carboxamide of phenylpiracetam (fonturacetam) is replaced by a carbohydrazide group. First synthesized in 1980 by a Russian medicinal-chemistry group screening 4-phenyl-2-pyrrolidinone derivatives for anticonvulsant activity, it has never been approved as a drug in any jurisdiction and has no human clinical trial data. The parent compound phenylpiracetam is explicitly listed on the WADA Prohibited List under S6.A (Non-Specified Stimulants); the hydrazide analog's own it is not on the WADA Prohibited List (only beta-2 agonists are prohibited, Category S3). It is sold by gray-market research-chemical vendors labeled 'not for human consumption.'

Mechanism of Action

No mechanism of action has been experimentally established for phenylpiracetam hydrazide in any primary source. The original 1980 Russian synthesis program screened it for anticonvulsant activity in an electroshock seizure assay (behavioral endpoint), not receptor-binding or molecular mechanism studies. Proposed mechanisms for the parent compound phenylpiracetam (e.g., AMPA-receptor or dopaminergic/cholinergic modulation) have not been demonstrated for this hydrazide derivative.

Research Summary

No human clinical trials have been conducted; no ClinicalTrials.gov record or DrugBank entry exists. The sole preclinical finding is from the 1980 Glozman et al. synthesis paper: an ED₅₀ of approximately 310 mg/kg for seizure protection in a rodent electroshock assay (species, strain, sex, and route not fully recoverable from accessed sources). No published human toxicology, LD₅₀, pharmacokinetics, or adverse-event data were located for this compound.

Reported Side Effects

• No published human toxicology or adverse-event data
• Parent compound phenylpiracetam is WADA-prohibited (S6.A Non-Specified Stimulants); hydrazide analog's doping status unconfirmed
• FDA treats piracetam-class analogs sold as supplements as unapproved new drugs (class-level statement)
• Gray-market availability with no regulatory safety clearance
• Unknown impurity profile or manufacturing standards

Compare Phenylpiracetam hydrazide with Others

Research References

• Phenylpiracetam hydrazide, Compound Summary (CID 4995664).
• PHENYLPIRACETAM HYDRAZIDE — GSRS substance record (UNII 289199VKN4).
• Synthesis and anticonvulsive activity of 4-phenyl-2-pyrrolidinone-1-acetic acid amides (Glozman et al.). 1980.
• Increasing use of an unapproved drug alleging performance enhancing benefits: piracetam analogs in dietary supplements. 2020. PMID 31764936.

Frequently asked questions

Has Phenylpiracetam hydrazide been independently lab-tested?

Disclosed Labs has collected 2 Certificates of Analysis (COA) for Phenylpiracetam hydrazide from 2 independent testing labs. 1 vendor has submitted material for testing. Products average 99.4% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/phenylpiracetam-hydrazide/testing.

How does Phenylpiracetam hydrazide work?

No mechanism of action has been experimentally established for phenylpiracetam hydrazide in any primary source. The original 1980 Russian synthesis program screened it for anticonvulsant activity in an electroshock seizure assay (behavioral endpoint), not receptor-binding or molecular mechanism studies. Proposed mechanisms for the parent compound phenylpiracetam (e.g., AMPA-receptor or dopaminergic/cholinergic modulation) have not been demonstrated for this hydrazide derivative.

What does the research say about Phenylpiracetam hydrazide?

No human clinical trials have been conducted; no ClinicalTrials.gov record or DrugBank entry exists. The sole preclinical finding is from the 1980 Glozman et al. synthesis paper: an ED₅₀ of approximately 310 mg/kg for seizure protection in a rodent electroshock assay (species, strain, sex, and route not fully recoverable from accessed sources). No published human toxicology, LD₅₀, pharmacokinetics, or adverse-event data were located for this compound.